Yangzijiang tamoxifen, Anaquzole first through the consistency evaluation

recently, Yangzijiang Pharmaceutical Group taxifen tablets (10mg), anaquzoltableta (1mg) two anti-tumorproducts(http://the first by the imitation ofpharmaceutical(http://quality and efficacy consistency evaluationbreast cancer is the most common malignant tumor in women, with mortality rate second only to lung cancerIn addition to surgery, the treatment of breast cancer includes endocrine therapy, radiotherapy, chemotherapy and targeted therapy, and the treatment of tamoxifen and anazole are commonly used in breast cancerthe drug(http://tamoxifen is mainly used to treat recurrent metastatic breast cancer in women, as well as to assist in the treatment of metastasis after breast cancer surgeryThe first-line drug for postmenopausal HER2-negative metastatic breast cancer recommended by AGO guidelines in 2015 was added to China's new national health insurance directory in 2017an aphorolin tablets are mainly used as complementary treatments for early breast cancer sympathisers that are positive for hormone receptors in postmenopausal womenIt inhibits the conversion of oxycodone in the adrenal glands of postmenopausal patients into estrogen, which significantly reduces plasma estrogen levels, inhibits the growth of breast tumors, and obtains the recommendations of several authoritative experts and diagnostic guidelinesstarting from 2014, Yangzijiang Pharmaceutical Group adheres to the highest standards to promote the quality and efficacy of generic drugs consistency evaluation work, has started more than 60 chemicaldrug (http:// re-evaluation, currently through the consistency evaluation of the number of products reached 8, 6 of which are the first in the country to pass, and more than 20 varieties to complete the declaration, and in the review state